1. Indonesia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PT Kalbe Farma Tbk

PT Kalbe Farma Tbk

0.03
EUR
0.00
(0.00%)
1.36BMarket Cap
Nov 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
341.38
370.53
381.6
413.32
430.55
449.58
482.85
493.09
560.26
622.01
658.28
706.43
775.95
- -
Basic EPS, GAAP
40.95
44.08
42.76
49.06
51.28
52.42
53.48
58.31
67.92
72.71
59.81
70.16
80.51
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
19
17
19
19
22
25
26
26
28
35.07
38
31.05
35.93
- -
Book Value per Share
172.56
199.04
223.26
254.06
283.32
311.97
339.05
371.33
417.71
440.71
463.05
495.93
514.78
537.67
Tangible Book Value per Share
164.34
190.04
214.33
244.81
273.47
301.13
323.83
356
392.74
407.28
424
445.24
463.64
486.77
Basic Weighted Avg Shares
46,875
46,875
46,875
46,875
46,875
46,875
46,875
46,873
46,873
46,516
46,256
46,187
45,524
45,276
Sales/Revenue/Turnover
16,002,131
17,368,533
17,887,464
19,374,231
20,182,120
21,074,306
22,633,476
23,112,655
26,261,195
28,933,503
30,449,134
32,627,776
35,324,544
- -
Operating Margin (%)
16.23
16.19
15.03
16.08
16.01
15.06
14.6
15.36
15.25
14.6
11.91
12.47
12.87
- -
Depreciation Expense
152,451
191,582
217,384
268,063
281,239
262,344
270,261
338,879
348,081
333,775
333,650
326,810
365,956
- -
Net Income, GAAP
1,919,508
2,066,022
2,004,237
2,299,735
2,403,606
2,457,129
2,506,765
2,733,260
3,183,621
3,382,210
2,766,748
3,240,637
3,664,998
- -
Effective Tax Rate (%)
23.4
23.25
24.37
23.95
24.31
24.47
25.42
22.83
21.99
22.62
22.96
23.05
21.64
- -
Profit Margin (%)
12
11.9
11.2
11.87
11.91
11.66
11.08
11.83
12.12
11.69
9.09
9.93
10.38
- -
Working Capital
4,856,729
5,734,885
6,379,585
7,255,368
7,815,403
8,362,121
8,645,382
9,899,105
12,177,553
12,279,191
12,674,556
13,001,919
13,172,183
14,328,870
LT Debt
- -
44,220
130,933
134,417
145,603
260,002
647,688
788,552
532,509
311,899
318,779
220,048
163,720
175,831
Total Equity
8,479,392
9,764,101
10,938,286
12,463,847
13,894,032
15,294,595
16,705,582
18,276,082
21,265,878
22,097,328
23,120,022
24,590,434
24,728,503
25,764,068
Return on Invested Capital (%)
22.87
21.43
18.04
18.65
17.51
15.93
14.77
14.27
14.87
14.3
11.82
12.67
14.3
- -
Return on Capital (%)
22.59
21.32
18.3
18.79
17.61
16.29
15.07
14.75
15.34
14.82
11.99
13.41
14.4
- -
Return on Common Equity (%)
25.35
23.72
20.25
20.56
19.08
17.61
16.43
16.42
17.22
16.93
13.24
14.66
15.9
- -

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
133,563
132,749
649,523
LT Borrowings
143,018
146,395
155,165
LT Finance Leases
20,702
25,112
20,666
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45,287
45,249
45,249
Market Capitalization
54,457,596
39,999,030
27,848,753

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
18,508,334
19,914,964
20,983,437
Cash, Cash Equivalents & STI
4,485,583
4,546,502
4,985,231
Accounts Receivable, Net
5,651,335
6,337,303
6,582,713
Inventories
6,985,130
7,414,554
7,923,721
Total Current Liabilities
5,336,151
5,599,976
6,654,567
Payables & Accruals
- -
- -
- -
ST Debt
133,563
132,749
649,523
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.6%
6.36%
0.56%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
6.73%
6.95%
13.09%
Sales/Revenue/Turnover
7.09%
8.89%
8.27%
Total Cash Common Dividend
- -
7.08%
14.08%

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,363,029
7,965,223
7,910,511
8,389,013
32,627,776
2025
8,788,190
8,233,926
- -
9,336,247
35,324,544
2026
9,678,361
9,800,446
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20.7
18.33
12.42
18.76
70.16
2025
23.57
19.78
- -
22.82
80.51
2026
22.74
19.68
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
31.05
2025
- -
- -
- -
- -
35.93
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bernadette Ruth Setiady
Full Time Employees
12,835
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Gedung KALBE Jakarta JK Indonesia 10510
IPO Date
Jul 30, 1991
Website
kalbe.co.id
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PT Kalbe Farma Tbk (KLBF.JK) develops, manufactures, and trades pharmaceutical products in Indonesia, operating through four primary divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistics. The company offers prescription drugs including generic, branded generics, and licensed products in therapeutic areas such as neurology, cardiology, infectious diseases, diabetes, and cardiovascular treatments; consumer health products encompassing over-the-counter drugs, energy drinks like Extra Joss, cough and cold remedies such as Mixagrip and Komix, vitamins, supplements, pain relievers, and digestive aids like Promag; nutritional products for infants (e.g., infant formula, growing-up milk), children, adults, pregnant and lactating women, elders, and special medical needs (e.g., Diabetasol, Prenagen, Fitbar); distribution and logistics services including warehousing, transportation, and supply chain management for healthcare products; as well as health services via Mitrasana Clinics, medical devices, biopharma, animal health solutions, E-health offerings, and biotechnology research in stem cells and drugs. Established in 1966 and headquartered in Jakarta at Gedung Kalbe, Jl. Let. Jend. Suprapto Kav. 4, the company primarily serves the Indonesian market with a distribution network reaching over one million outlets and extends operations to Southeast Asia including exports and international business. Recent developments include a strategic partnership with GC Cell via subsidiary PT Bifarma Adiluhung for cell therapy introduction such as Immuncell-LC injection in Indonesia; memorandum of understanding and joint venture establishment with Livzon Pharma Indonesia in May and July 2024 for manufacturing pharmaceutical ingredients targeting domestic and export markets in diabetes, cardiovascular, and vaccines; exclusive collaboration with Alliance Pharma Co., Ltd. (Thailand) in 2024 to enhance Southeast Asia penetration particularly Thailand; new product launches in 2024 for domestic and ASEAN marketing; and advancement of radiopharmaceutical facilities including cyclotron completion in 2022 with ongoing focused therapeutic expansions.